Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates
10:16am, Thursday, 06'th Nov 2025
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago.
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
08:15am, Wednesday, 29'th Oct 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term s
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 17'th Oct 2025
SAN CARLOS, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health
06:17am, Friday, 17'th Oct 2025
Here's a great way to earn strong market returns over the long term: Identify companies that have been ignored or underestimated by most investors but have attractive prospects; buy their shares at a
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire?
05:53am, Monday, 13'th Oct 2025
Most investors don't truly expect a single, relatively small trade to explode into a seven-figure holding. On the other hand, the prospect can't be entirely ruled out either.
Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play
10:30am, Friday, 10'th Oct 2025
Iovance Biotherapeutics (IOVA) maintains a Buy rating, supported by growing Amtagvi sales, promising efficacy data, and ongoing label expansion opportunities. IOVA's restructuring aims to cut over $10
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options If you are a long-term s
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:00pm, Friday, 19'th Sep 2025
SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and del
Can This Beaten-Down Stock Bounce Back?
10:05am, Friday, 19'th Sep 2025
Last year, Iovance Biotherapeutics (IOVA -1.59%), a small-cap biotech, made a major breakthrough. The company earned approval for Amtagvi, which became the first medicine of its kind to receive regula
Iovance Biotherapeutics to Present at Upcoming Conferences
08:30am, Friday, 29'th Aug 2025
SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf
If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today
04:28pm, Wednesday, 27'th Aug 2025
For a roller-coaster stock, look no further than Iovance Biotherapeutics (IOVA -1.22%).
IOVA Stock Drops 6% on $350M Common Stock Offering
10:20am, Tuesday, 26'th Aug 2025
Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline.
Why Iovance Biotherapeutics Stock Got Mashed on Monday
05:15pm, Monday, 25'th Aug 2025
Monday won't go down as a particularly memorable trading session on the stock market. It also won't be marked as a great day for shareholders of biotech Iovance Biotherapeutics (IOVA -5.95%).
1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street
09:30am, Sunday, 24'th Aug 2025
There's at least one good thing to say about Iovance Biotherapeutics (IOVA 5.71%), a small-cap biotech. The drugmaker is an innovative company.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 22'nd Aug 2025
SAN CARLOS, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
